公开(公告)号：US11766435B2

公开(公告)日：2023-09-26

申请号：US16076400

申请日：2017-02-13

申请人： Merck Sharp & Dohme LLC ,  The Walter and Eliza Hall Institute of Medical Research

发明人： Tanweer A. Khan ,  Jared N. Cumming ,  David B. Olsen ,  Justin A. Boddey ,  Alan F. Cowman ,  Brad E. Sleebs

IPC分类号： A61K31/4709 ,  A61K9/06 ,  A61K47/10 ,  A61K47/12 ,  A61P17/10 ,  A61P17/00 ,  A61P17/04 ,  A61P31/04 ,  A61K31/513 ,  A61P33/06 ,  A61K31/527 ,  A61K9/00 ,  A61K45/06

CPC分类号： A61K31/513 ,  A61K31/527 ,  A61P33/06 ,  A61K9/0019 ,  A61K9/0053 ,  A61K45/06

摘要： The present invention provides methods of treating malaria comprising administration of an N3-substituted iminopyrimidinone of Formula (I) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables R1, R2, R3, R4, R5, A, B, L, m, and n are as defined herein. The invention also provides uses of the compounds of Formula (I), as defined herein, for inhibiting plasmepsin V activity, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.

公开(公告)号：US20230263778A1

公开(公告)日：2023-08-24

申请号：US17905601

申请日：2021-03-23

申请人： John M.H. Gregg

发明人： John M.H. Gregg

IPC分类号： A61K31/427 ,  A61K31/496 ,  A61K31/352 ,  A61K31/675 ,  A61K31/513 ,  A61K31/573 ,  A61K9/00

CPC分类号： A61K31/427 ,  A61K31/496 ,  A61K31/352 ,  A61K31/675 ,  A61K31/513 ,  A61K31/573 ,  A61K9/007

摘要： This invention relates to the use of anti viral drugs with different mechanisms of action for the treating or preventing of viral infections such as COVID-19 (also known as SARS˜CoV-2) and reducing medical complications related to COVID-19 viral disease. The present invention also relates to compositions and combinations of new antiviral drags formed from existing drugs with antiviral activity, and the administration of these compounds used in these various new combinations that are incorporated into pulmonary and oral delivery systems.

公开(公告)号：US20230255972A1

公开(公告)日：2023-08-17

申请号：US18015616

申请日：2021-07-14

申请人： TAIHO PHARMACEUTICAL CO., LTD.

发明人： Kei OGUCHI ,  Yuki SHIKATA ,  Junya IWASAKI

IPC分类号： A61K31/519 ,  A61K31/7068 ,  A61K39/395 ,  A61K31/513 ,  A61K33/243 ,  A61K31/337 ,  A61K31/5377 ,  A61K31/565 ,  A61K31/4745 ,  A61K31/436 ,  A61K31/553 ,  A61K31/4375 ,  A61P35/00

CPC分类号： A61K31/519 ,  A61K31/7068 ,  A61K39/3955 ,  A61K31/513 ,  A61K33/243 ,  A61K31/337 ,  A61K31/5377 ,  A61K31/565 ,  A61K31/4745 ,  A61K31/436 ,  A61K31/553 ,  A61K31/4375 ,  A61P35/00

摘要： Provided is a tumor treatment method using a pyrimidine compound or a salt thereof. An antitumor agent that contains a pyrimidine compound represented by general formula (I) or a salt thereof, said antitumor agent being to be administered in combination with another antitumor agent. (In the formula, R1 represents a C1-C4 alkyl group optionally having a C1-C4 alkoxy group as a substituent, or a C3-C4 cycloalkyl group; R2 represents a hydrogen atom, a halogen atom, a C1-C6 alkyl group optionally having, as a substituent(s), one to five C1-C4 alkoxy groups or one to five fluorine atoms, or a C1-C6 alkoxy group; R3 represents a hydrogen atom, or a C1-C4 alkyl group optionally having, as a substituent(s), one to five fluorine atoms; R4 represents a hydrogen atom or a C1-C4 alkyl group; and R5 represents a phenyl group optionally having one to three substituents selected from fluorine atoms and chlorine atoms.)

公开(公告)号：US20230255968A1

公开(公告)日：2023-08-17

申请号：US18168221

申请日：2023-02-13

申请人： AbbVie Inc. ,  Neurocrine Biosciences, Inc.

发明人： Jayanthy Jayanth ,  Kevin C. Spence ,  Gregory A. McClelland ,  Anna V. Stepanenko ,  Kristof Chwalisz ,  Charlotte D. Owens ,  James W. Thomas ,  Jane Castelli-Haley ,  Keith Gordon ,  Michael C. Snabes ,  Ahmed M. Soliman ,  Geoff Zhang ,  David Metzger ,  Yanxia Li ,  Tzuchi R. Ju ,  Xi Shao ,  Oscar Antunez Flores ,  Rita Jain ,  Juki Wing-Keung Ng ,  Janine D. North ,  Hannah Palac ,  Paul M. Peloso

IPC分类号： A61K31/513 ,  A61K9/20 ,  A61P5/30 ,  A61P15/00

CPC分类号： A61K31/513 ,  A61K9/2009 ,  A61K9/2018 ,  A61P5/30 ,  A61K9/2059 ,  A61P15/00 ,  A61K9/2027

摘要： The present disclosure relates to pharmaceutical compositions comprising a gonadotropin-releasing hormone (GnRH) antagonist and methods of preparing and using such compositions. The disclosure also relates to methods of facilitating release of a GnRH antagonist from a pharmaceutical composition.

公开(公告)号：US11723907B2

公开(公告)日：2023-08-15

申请号：US16488096

申请日：2018-02-23

申请人： THE CLEVELAND CLINIC FOUNDATION

发明人： Jaroslaw Maciejewski ,  Sergei Vatolin

IPC分类号： A61K31/513 ,  A61K31/136

CPC分类号： A61K31/513 ,  A61K31/136

摘要： Anti-aging compounds identified using the lead compounds violuric acid and 1-naphthoquinone-2-monoxime are described. The compounds are redox catalysts that appear to improve the function of hematopoietic stem cells. The compounds can be used to decrease the rate of aging in a subject, or to treat or decrease the risk of developing an age-related disease or disorder.

公开(公告)号：US20230251276A1

公开(公告)日：2023-08-10

申请号：US18102852

申请日：2023-01-30

申请人： Cognizance Biomarkers LLC

发明人： Todd WALLACH ,  Peter CRINO ,  John POLLARD ,  Elizabeth BRAND ,  Maura STRAUMAN ,  Christopher HOLLENBEAK ,  Richard ST. CLAIR ,  Jeffrey BOTBYL ,  John GLEDHILL

IPC分类号： G01N33/68 ,  A61K31/27 ,  A61K31/4166 ,  A61K31/515 ,  A61K31/55 ,  A61K31/4015 ,  A61K31/195 ,  A61K31/20 ,  A61K31/513 ,  A61K31/5513 ,  A61K31/53 ,  A61K31/551

CPC分类号： G01N33/6896 ,  A61K31/27 ,  A61K31/4166 ,  A61K31/515 ,  A61K31/55 ,  A61K31/4015 ,  A61K31/195 ,  A61K31/20 ,  A61K31/513 ,  A61K31/5513 ,  A61K31/53 ,  A61K31/551 ,  G01N2800/2857

摘要： Epileptic seizures are difficult to diagnose and are often difficult to distinguish from several conditions with similar presentations, and therefore, diagnosis of seizures is often a long, expensive, and unreliable process. This invention provides biomarkers for identifying seizures and epilepsy, assays for measuring and assessing biomarker concentration, predictive models based on biomarkers and computer systems for detecting, assessing and diagnosing phasic and tonic changes associated with seizures and epilepsy in all clinical and healthcare settings. Diagnostic methods, kits and predictive models provided herein provide quantitative and/or qualitative assessment in order to allow patients to proceed immediately to diagnostic and/or treatment protocols, and assess therapeutic treatment effectiveness.

公开(公告)号：US20230250176A1

公开(公告)日：2023-08-10

申请号：US18166769

申请日：2023-02-09

申请人： Dragonfly Therapeutics, Inc.

发明人： Ann F. Cheung ,  Jean-Marie Cuillerot ,  Mark DeRose ,  Stacey V. Drabic ,  Asya Grinberg ,  Zong Sean Juo ,  Aaron Levin ,  Katia Liharska ,  Lynn Markowitz ,  Christopher Ryan Morgan ,  Avni Shah ,  Michael Shifrin ,  Nicolai Wagtmann

IPC分类号： C07K16/28 ,  A61K47/12 ,  A61K47/26 ,  A61K39/395 ,  A61K31/138 ,  A61K31/167 ,  A61K31/513 ,  A61K33/243 ,  C07K1/22 ,  A61P35/00

CPC分类号： C07K16/2863 ,  C07K16/2851 ,  A61K47/12 ,  A61K47/26 ,  C07K16/2818 ,  C07K16/2827 ,  A61K39/3955 ,  A61K31/138 ,  A61K31/167 ,  A61K31/513 ,  A61K33/243 ,  C07K1/22 ,  A61P35/00 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2317/55

摘要： Described herein are pharmaceutical formulations comprising multi-specific binding proteins that bind to NKG2D, CD16, and epidermal growth factor receptor (EGFR); and therapeutic uses of the multi-specific binding proteins and pharmaceutical formulations thereof for treating a disease, for example, cancer, in a patient in need thereof.

公开(公告)号：US11707444B2

公开(公告)日：2023-07-25

申请号：US17465847

申请日：2021-09-03

申请人： RESEARCH COOPERATION FOUNDATION OF YEUNGNAM UNIVERSITY ,  KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

发明人： Jintae Lee ,  Jungyeob Ham ,  Taejung Kim

IPC分类号： A61K31/352 ,  A61K31/192 ,  A61K31/05 ,  A61K31/513 ,  A61K31/4706 ,  A61P31/14 ,  A61K36/185 ,  G01N33/94 ,  G01N33/569 ,  A61K31/675

CPC分类号： A61K31/352 ,  A61K31/05 ,  A61K31/192 ,  A61K31/4706 ,  A61K31/513 ,  A61K31/675 ,  A61K36/185 ,  A61P31/14 ,  G01N33/56983 ,  G01N33/948 ,  G01N2333/165 ,  G01N2500/04

摘要： The present invention relates to an antiviral composition and a screening method thereof for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that occurred in Wuhan, China in 2019. An extract from leaves or unfertilized female flowers of Cannabis sativa L. or its fraction, and the cannabinoids (CBDs) molecules isolated from it have high binding strength and stability to SARS-CoV-2 MPpro, thereby inhibiting its action as the main protease, to provide a useful lead molecule that can be used alone or in combination with other drugs to treat SARS-CoV-2.

公开(公告)号：US20230226149A1

公开(公告)日：2023-07-20

申请号：US18002420

申请日：2021-06-17

申请人： Lung Therapeutics, Inc.

发明人： BreAnne MACKENZIE ,  Cory HOGABOAM ,  Brian WINDSOR

IPC分类号： A61K38/17 ,  A61K31/4706 ,  A61K31/675 ,  A61K31/4965 ,  A61K31/513 ,  A61K31/427

CPC分类号： A61K38/177 ,  A61K31/4706 ,  A61K31/675 ,  A61K31/4965 ,  A61K31/513 ,  A61K31/427

摘要： Provided herein are methods of using modified caveolin-1 (Cav-1) peptides to treat or prevent pathogen-induced lung injury and disrepair. In particular, provided are methods of using the modified Cav-1 peptides for the treatment of pathogen-induced lung injury and disrepair caused by a coronavirus, such as, for example, SARS-CoV-2.

公开(公告)号：US20230218755A1

公开(公告)日：2023-07-13

申请号：US18183467

申请日：2023-03-14

申请人： Genentech, Inc.

发明人： Gwendolyn FYFE ,  Eric HOLMGREN ,  Robert D. MASS ,  William NOVOTNY

IPC分类号： A61K39/395 ,  C07K16/22 ,  A61K31/525 ,  A61K31/519 ,  C07K16/30 ,  A61K31/4545 ,  A61K9/00 ,  A61K38/50 ,  A61K31/337 ,  A61K31/282 ,  A61K38/09 ,  A61K31/555 ,  A61K31/522 ,  A61K31/573 ,  A61K38/21 ,  A61K31/513 ,  A61K31/7068 ,  A61K31/4745 ,  A61K45/06 ,  A61K39/00

CPC分类号： A61K39/3955 ,  C07K16/22 ,  A61K31/525 ,  A61K31/519 ,  C07K16/3046 ,  A61K31/4545 ,  A61K9/0019 ,  A61K39/39541 ,  A61K38/50 ,  A61K31/337 ,  A61K31/282 ,  A61K38/09 ,  A61K31/555 ,  A61K31/522 ,  A61K31/573 ,  A61K38/212 ,  A61K31/513 ,  A61K31/7068 ,  A61K39/39558 ,  A61K31/4745 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/567 ,  C07K2317/565 ,  C07K2317/24 ,  C07K2317/76 ,  C07K2317/21

摘要： This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.